Search results
Showing 7276 to 7290 of 7707 results
In development [GID-TA10926] Expected publication date: TBC
In development [GID-TA10905] Expected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development [GID-TA11010] Expected publication date: TBC
In development [GID-TA11318] Expected publication date: TBC
In development [GID-TA10917] Expected publication date: TBC
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
This guidance has been updated and replaced by NICE diagnostics guidance 58.
Flow transcranial direct current stimulation for treating depression (MIB324)
May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.
Parkinson's disease with motor fluctuations: safinamide (ES6)
This evidence summary has been updated and replaced by NICE guideline NG71.
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development [GID-TA10858] Expected publication date: TBC